Wire · opportunities
FDA approves Tivicay pd for youngest HIV patients
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 September 2026 · Fusion42 review
The US FDA approved Tivicay PD for use in newborns weighing at least 2 kg with HIV-1, making it the first second-generation integrase inhibitor authorised for this population and expanding paediatric HIV treatment options.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 4 sources have reported it between 26 Aug 2026 and 3 Sep 2026.
◆ ◆ The Wire takeaway
You can now target newborn HIV patients with a modern, approved integrase inhibitor therapy, opening a critical early treatment window that few competitors address. This approval cuts through regulatory barriers that previously limited infant treatment choices.
◆ Coverage
4 sources · first reported 26 Aug 2026 · latest 3 Sep 2026
◆ Related on Wire
◆ Topics